UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 ______________________________________ For the quarterly period ended March 31, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Registrant's telephone number, including area code: (510) 982-6030 ______________________________________ Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par ...

Exhibit 99.1 Caribou Biosciences Reports First Quarter 2024 Financial Results and Provides Business Update -- Expanding into autoimmune diseases with IND cleared for CB-010 in lupus nephritis and extrarenal lupus; GALLOP Phase 1 clinical trial expected to initiate by YE 2024 -- -- $345.9 million in cash, cash equivalents, and marketable securities expected to fund the current operating plan into Q1 2026 -- "We continue to focus on advancing four clinical-stage programs, including the parallel development of ...

BERKELEY, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced two abstracts have been accepted for poster presentations at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held May 31-June 4, 2024 in Chicago, Illinois. The ANTLER poster will provide initial dose expansion data. Details of the poster presentation are as follows: Title: A CRISPR-edited a ...

Solskin Caribou Biosciences, Inc. (NASDAQ:CRBU) is gearing up to present initial dose expansion data from its ongoing phase 1 ANTLER study. This particular early-stage study uses CB-010 for the treatment of patients with 2nd-line relapsed or refractory large B cell lymphoma [r/r LBCL]. Positive data from the dose-escalation portion of the study was already released. What investors can look forward to regarding the advancement of this program would be two catalysts in particular. The first catalyst would be ...

-- FDA has cleared Caribou's IND application for CB-010 in lupus nephritis and extrarenal lupus; GALLOP Phase 1 clinical trial expected to initiate by YE 2024 -- -- Driven by encouraging initial safety and efficacy in the ongoing ANTLER trial for r/r B-NHL, CB-010 clinical development has expanded to include autoimmune diseases -- -- Advancing ANTLER Phase 1 trial for 2L LBCL; initial dose expansion data to be shared at a medical congress in Q2 2024 -- -- Conference call and webcast scheduled for today at 5 ...

Investors might want to bet on Caribou Biosciences, Inc. (CRBU) , as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the sy ...

Shares of Caribou Biosciences (CRBU -24.03%) were crashing 19.7% lower as of 11:13 a.m. ET on Tuesday. The big sell-off came after the biotech provided its fourth-quarter update on Monday.Caribou reported fourth-quarter licensing revenue of $3.6 million and a net loss of $34.5 million. However, the big story with the clinical-stage biotech's quarterly update was the pause in developing allogeneic cell therapy CB-020. How worrisome is Caribou Biosciences' development pause?It's not surprising that Caribou's ...

• Bridging therapy often required. Long wait times between the initial collection of the patient's T cells and the return of the manufactured cells back to the patient may require bridging therapy, an additional line of therapy. • Manufacturing constraints. At present, there are a limited number of CAR-T cell centers and there are often insufficient manufacturing slots available to meet patient demand for autologous therapies. In addition, autologous cell manufacturing is complex and lengthy, and there can ...

BERKELEY, Calif., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the company’s participation in the following investor conferences: Citi's 2024 Virtual Oncology Leadership SummitFebruary 21, 2024, fireside chat at 12:00 pm EST Leerink Global Biopharma ConferenceMarch 12, 2024, fireside chat at 1:40 pm EDT Barclays Global Healthcare ConferenceMarch 13, 2024 H.C. Wainwright 2nd Annual Cell Th ...

Cash Used in Operating Activities 32 During the nine months ended September 30, 2023, cash used in investing activities was $36.7 million, and during the nine months ended September 30, 2022, cash used in investing activities was $94.4 million. During the nine months ended September 30, 2023, and 2022, cash provided by financing activities was $154.3 million and $2.0 million, respectively. Our critical accounting policies are disclosed in our audited consolidated financial statements for the year ended Dece ...